A clinical trial to examine an improvement of implantation with an administration of Hishi extract.

A prospective randomized open-label controlled clinical trial to examine an improvement of implantation with an administration of Hishi extract. - Hishi extract and implantation

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000045017

Enrollment

210

Registered

2021-07-30

Start date

2021-07-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Infertile women who meet inclusion criteria and do not meet exclusion criteria are prospectively allocated into two groups of A (Hishi group) and B (control group) at random. Women can freely decide t

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: The study includes infertile women who satisfy all the following criteria; (1) she is planning to have cryopreserved-thawed blastocyst transfer (CT-BT) in natural cycles, (2) she has failed to deliver with 1-3 attempts of embryo transfer containing at least one superior blastocyst or cleaving embryo, (3) embryos used in the planning CT-BT must include at least one superior blastocyst when they were cryopreserved, which were produced by ovarian stimulation using long protocol, antagonist protocol, clomiphene citrate-hMG protocol, or PPOS, and (4) 42 years old or younger on the date of oocyte retrieval when she cryopreserved blastocysts which is used in the planning CT-BT.

Exclusion criteria

Exclusion criteria: Women are excluded when they meet any of the following criteria; (1) organic uterine infertility (Asherman syndrome, uterine anomaly, and submucosal myoma larger than 1.5 cm in diameter), (2) severe diminished ovarian reserve (AMH<0.01 ng/mL, day-3 FSH > 15 IU/L, day-3 E2 > 70pg/mL, or no ovary observed under ultrasound), (3) diabetes or taking anti-diabetic medicine, and (4) having her partner with azoospermia.

Design outcomes

Primary

Measure	Time frame
Birth rate per embryo transfer	—

Secondary

Measure	Time frame
Birth rate per hCG positive, rates of implantation, clinical pregnancy, viable pregnancy, and ongoing pregnancy per transfer, and AGE levels in the endometrium.	—

Countries

Japan

Contacts

Public ContactMasao Jinno

Women's Clinic Jinno Reproductive Medicine

mjinno@s9.dion.ne.jp042-480-3105

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026